New insider activity at Exelixis ( (EXEL) ) has taken place on February 26, 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Exelixis has seen notable insider activity as Aftab Dana, the company’s Executive Vice President of Research and Development, sold 47,918 shares of Exelixis stock in a recent transaction. The total value of the sale amounted to $2,132,351, highlighting a substantial move by a key member of the leadership team involved in the company’s research and development efforts.
Recent Updates on EXEL stock
Exelixis shares reacted to a Q4 update that paired solid cabozantinib growth and in-line revenue with rising cost and pricing headwinds. Analysts’ recent target revisions have centered on durable CABOMETYX demand, the FDA’s acceptance of the zanzalintinib NDA in metastatic colorectal cancer, and a broad multi-tumor ZANZA trial program, partly offset by higher gross-to-net pressures and elevated R&D and commercial spending.
Spark’s Take on EXEL Stock
According to Spark, TipRanks’ AI Analyst, EXEL is a Outperform.
The score is primarily supported by strong financial performance (scaling revenue, expanding profitability, and robust cash generation with low leverage) and a constructive earnings call emphasizing CABOMETYX momentum plus ZANZA regulatory progress and ongoing buybacks. These positives are tempered by mixed technical momentum (negative MACD) and near-term risks highlighted on the call, including rising operating expenses, higher gross-to-net deductions, and remaining clinical/regulatory uncertainty.
To see Spark’s full report on EXEL stock, click here.
More about Exelixis
YTD Price Performance: 2.10%
Average Trading Volume: 2,579,305
Technical Sentiment Signal: Strong Buy
Current Market Cap: $11.72B